title: [Use of monoclonal antibodies to tumor necrosis factor (remicade) in rheumatoid arthritis: preliminary results].
abstract: OBJECTIVE
  To study effectiveness and tolerance of monoclonal antibodies to tumor necrosis factor (the drug remicade) in patients with rheumatoid arthritis (RA).
  
  
  METHODS
  Remicade treatment results are considered for 25 RA patients receiving methotrexate the activity of which was inadequate for these patients. Remicade was infused intravenously in a dose 200 mg 4 times for 22 weeks.
  
  
  RESULTS
  Remicade produced positive clinical and laboratory effects as early as the first infusion. The response was observed during 22 weeks of the treatment in 17 of 25 patients. Remicade tolerance was good. One patient failed the treatment because of development of collapse.
  
  
  CONCLUSIONS
  Pilot results of remicade trial point to its high therapeutic potential and perspectives in rheumatology.
authors.forename: G V
authors.initials: GV
authors.lastname: Lukina
authors.forename: Ia A
authors.initials: IaA
authors.lastname: Sigidin
authors.forename: N V
authors.initials: NV
authors.lastname: Chichasova
authors.forename: R M
authors.initials: RM
authors.lastname: Balabanova
authors.forename: A G
authors.initials: AG
authors.lastname: Belenkiĭ
authors.forename: G R
authors.initials: GR
authors.lastname: Imametdinova
authors.forename: V G
authors.initials: VG
authors.lastname: Barskova
authors.forename: A G
authors.initials: AG
authors.lastname: Bochkova
authors.forename: D A
authors.initials: DA
authors.lastname: Gukasian
authors.forename: O N
authors.initials: ON
authors.lastname: Egorova
authors.forename: D E
authors.initials: DE
authors.lastname: Karateev
authors.forename: I R
authors.initials: IR
authors.lastname: Kolosova
authors.forename: E Iu
authors.initials: EIu
authors.lastname: Loginova
authors.forename: E Iu
authors.initials: EIu
authors.lastname: Pudovkina
authors.forename: M L
authors.initials: ML
authors.lastname: Stanislav
authors.forename: L A
authors.initials: LA
authors.lastname: Taukumova
authors.forename: T P
authors.initials: TP
authors.lastname: Fedina
authors.forename: E L
authors.initials: EL
authors.lastname: Nasonov
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy*; D003627:Data Interpretation, Statistical; D005260:Female; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D010865:Pilot Projects; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab; D008727:Methotrexate